Clinical Trial Analysis of Targeted Therapeutic Options for BRAF-Mutated Metastatic Colorectal Cancer, Including Combination Therapies

Program Dates: July 10, 2020 - July 9, 2021
Credits: 0.5 AMA PRA Category 1 Credits™; 0.5 CNE Contact Hours

Clinical Trial Analysis of Targeted Therapeutic Options for BRAF-Mutated Metastatic Colorectal Cancer, Including Combination Therapies

Program Overview

In this module, Van Karlyle Morris, MD, along with Scott Kopetz, MD, PhD, course chair, will highlight current strategies for targeting MAPK signaling in colorectal cancer (CRC). Recent clinical trial data for BRAF-mutated CRC, particularly various survival outcomes data, will be reviewed and clinical relevance debated throughout the interview. The emerging role of immunotherapy will also be evaluated. Upon completion of this 30-minute module, learners will gain insight into the clinical implications of current trial data, including that of combination therapies.

Target Audience

Community oncologists, oncologists, advanced practitioners, oncology nurses, and other healthcare professionals involved in the care of patients with colorectal cancer

Learning Objective

  1. Analyze recent clinical trial data of current and emerging treatment options for the management of patients with BRAF mutated colorectal cancer


Scott Kopetz, MD, PhD
Department of Gastrointestinal Medical Oncology
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas




Van Karlyle Morris, MD
Department of Gastrointestinal Medical Oncology
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas



Disclosures of Conflict of Interest

It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CNE activity:

Faculty Relationship Identified With:
Scott Kopetz, MD, PhD Consultant/Advisor: Amal Therapeutics; Amgen Inc.; AstraZeneca Pharmaceuticals; Bayer Health; Biocartis; Boehringer Ingelheim International GmbH; Boston Biomedical, Inc.; EMD Serono Inc.; Eli Lilly and Company; Genentech Inc.; Holy Stone Healthcare Co., Ltd.; Karyopharm Therapeutics; MedImmune; Merck & Co., Inc.; Navire Pharma; Novartis Pharmaceuticals Corporation; Pierre Fabre; Roche; Redx Pharma; Symphogen

Research/Grant Support: Amgen Inc.; Array BioPharma; Biocartis; Eli Lilly and Company; EMD Serono Inc.; Genentech, Inc.; Guardant Health; MedImmune; Novartis Pharmaceuticals Corporation; Roche; Sanofi

Stock Option: MolecularMatch; Navire Pharma

Van Karlyle Morris, MD Consultant/Advisor: BioCarta; Servier

Research/Grant Support: Boehringer Ingelheim International GmbH; Incyte Corporation

Planners and Peer Reviewers

Timothy Hayes, MD, PhD; Kim Cheramie, MSN, RN-BC; Nicole Brestowski and Chelsey Benedek hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.

Accreditation Statement

In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation Statement

AcademicCME designates this live material for a maximum of 0.50 AMA PRA Category 1 Credits TM.

AcademicCME designates this enduring material for a maximum of 0.50 CNE Contact Hours, including 0.50 Pharmacotherapeutic Contact Hours (Provider Number P0491).

Financial Support

This activity has been supported by an independent educational grant from Pfizer Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Pfizer Inc. do not recommend the use of any agent outside of the labeled indications.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Method of Participation

In order to claim credit, participants must complete the following:

  1. Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
    2. Complete the Pre-Activity Questions
    3. Read or Review the activity content.
    4. Complete the Post-Activity Test Questions and Evaluation.
    5. Learners who receive a grade of 70% or better on the Post-Activity Test Questions andcomplete the Evaluation will receive appropriate credit as indicated (CME, CNE, and/or CPE credit).
  • CPE credit will be posted to the learner’s CPE Monitor profile within 60 days of completion.
  • CME and CNE credit will be issued appropriate certificate of completion.
  • Others may request a “certificate of completion”.
  1. Learners should claim only the credit commensurate with the extent of their participation in the activity.

CE Inquiries/Special Needs

For all CME/CNE inquiries or special needs, please contact [email protected].


Provided by: AcademicCME-web

Leave a Reply

Your email address will not be published. Required fields are marked *